Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
about
Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignanciesAdvances in targeting signal transduction pathwaysS100A8 contributes to drug resistance by promoting autophagy in leukemia cellsPI3K and cancer: lessons, challenges and opportunitiesPI3K and mTOR signaling pathways in cancer: new data on targeted therapies.Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment.Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics.Mammalian target of rapamycin (mTOR) activity dependent phospho-protein expression in childhood acute lymphoblastic leukemia (ALL)Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer.Molecular targeted approaches in mantle cell lymphoma.Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignanciesA Critical Role of the mTOR/eIF2α Pathway in Hypoxia-Induced Pulmonary Hypertension.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.Recent progress in targeting cancer.mTOR complex 2 signaling and functionsTargeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment.Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levelsThe pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia.Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberineRole of PI3K-AKT-mTOR and Wnt Signaling Pathways in Transition of G1-S Phase of Cell Cycle in Cancer Cells.A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemiaNK/T-cell lymphomas in childrenTargeting the PI3-kinase/Akt/mTOR signaling pathway.Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic target.Apigenin sensitizes colon cancer cells to antitumor activity of ABT-263.Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.TrkC promotes survival and growth of leukemia cells through Akt-mTOR-dependent up-regulation of PLK-1 and Twist-1.Mammalian target of rapamycin complex 2 (mTORC2) coordinates pulmonary artery smooth muscle cell metabolism, proliferation, and survival in pulmonary arterial hypertension.Targeting autophagy during cancer therapy to improve clinical outcomes.Mammalian TOR signaling to the AGC kinases.Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies.Autophagy in blood cancers: biological role and therapeutic implications.mTORC signaling in hematopoiesis.Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment.Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy.Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen.Therapeutic targeting of IL-7Rα signaling pathways in ALL treatment.Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential.Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia.mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression.
P2860
Q26829652-0EC9D16F-031E-4A45-9245-0587BC57D231Q27686983-55030D9C-39E5-4431-88AB-9A8443684A9DQ28538712-058857A0-B8B6-4B29-814C-9DE68496DC96Q30080017-C9EA45D7-EC19-4CE6-B69D-6D723CCA13D5Q34164683-7CE97E38-32CF-4D19-BE8E-E308E1E40DBBQ34260622-B9369C0A-1099-422B-B353-F0546EBE1D6AQ34365926-8707842F-FFC1-4230-9C20-5EBDB1684A91Q34661672-A0CA0673-14A9-4F4B-BC52-2F780636B1A1Q35000084-BA2DA950-B561-4AF0-9BCA-D805AC0E16AFQ35127368-F8304257-5BCB-4C9F-B2D4-C2C6AB72C671Q35669226-27B85F8C-F9F2-4D06-A43F-707BC8DAC2CDQ35676912-6424EE2D-64E4-4C0E-93DD-46BCBB41522BQ35679353-498F6129-1444-4E07-B17A-DD798F75F46DQ35740782-AC20DDB4-DBA9-43A9-BC2A-518D7E6B0577Q35878519-FCC36618-880A-484C-B555-1C61D3ABE265Q36286881-7DBFA085-2BE6-44E0-96B7-F17E57F1DA77Q36339232-227A6C50-6079-40D7-9D5A-FA303DC9748AQ36379644-20CD4581-ED99-4734-A00F-1BB56F8CACF8Q36556350-21471F07-FCED-4535-BBA6-8C8E797317ABQ36760689-70364286-ED8B-4C52-A903-F7BEE624C10EQ36926129-7483C32B-5CB5-4231-8AF5-055E30436D78Q36995625-D93557B3-6796-472F-84DE-366F07A4D273Q37265126-E2221182-C453-4FCF-B917-D0B9A79D823BQ37322437-2EA2116A-1EED-46C3-8D14-4D12D59A28B5Q37410515-BE96721B-A009-410A-8ECD-89209A653B68Q37460101-21099CDA-EB94-48E1-897A-F98631FF7451Q37462530-B1E1F6A9-242E-44DA-871C-0EB61E18BF40Q37670612-158332B2-1097-4EA6-8369-8869CE35B878Q37858077-B17B2F79-4741-406E-9D0E-A358A32528F5Q37943416-7FCE2DB3-84CD-4CFE-9C79-717CC0FB6B64Q38017727-A8DCD4A5-02FD-46E2-9D23-104726404C74Q38134372-384E6757-04F3-4A19-A038-2BE71FE94826Q38704683-C66BEE51-7EF1-42B1-8A13-0F82CB96EA5BQ38741294-CF777E8C-859F-4124-BDA8-2F2A2559A15DQ38762740-743B9D93-B2AD-4194-BDC1-B3B0076F5E38Q38785283-3E4300EB-1F48-4988-A085-C95BC6F7D71EQ38856941-76616752-A8C2-4163-A2AD-F3CA7700A34EQ39119297-F64FD341-B913-4C3B-8E10-938FF5797FDFQ39344848-69F6E5AF-5352-4E84-A1CE-329ACC03B8D1Q41817864-0A172BDE-1B94-4D85-87A0-21D78E2F6A87
P2860
Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Targeted inhibition of mTORC1 ...... acute lymphoblastic leukemia.
@en
Targeted inhibition of mTORC1 ...... acute lymphoblastic leukemia.
@nl
type
label
Targeted inhibition of mTORC1 ...... acute lymphoblastic leukemia.
@en
Targeted inhibition of mTORC1 ...... acute lymphoblastic leukemia.
@nl
prefLabel
Targeted inhibition of mTORC1 ...... acute lymphoblastic leukemia.
@en
Targeted inhibition of mTORC1 ...... acute lymphoblastic leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
Targeted inhibition of mTORC1 ...... l acute lymphoblastic leukemia
@en
P2093
A M Martelli
F Chiarini
F Melchionda
G Tabellini
M Battistelli
P Pagliaro
P2860
P2888
P304
P356
10.1038/LEU.2011.20
P577
2011-02-18T00:00:00Z